Molnupiravir & Nirmatrelvir/Ritonavir in the Treatment of Systemic Autoimmune Rheumatic Diseases

Molnupiravir (MP) and Nirmatrelvir/ritonavir (NM/R) were the first two orally administered antiviral drugs authorized to treat COVID-19. However, the last two phases of clinical trials testing MP and NM/R in COVID-19 were conducted in unvaccinated individuals and before the emergence of the Omicron variant. Additionally, clinical trials didn’t include people suffering from systemic autoimmune rheumatic diseases (SARDs).

Read More »

Caring for Autoimmunity & Long COVID with a Personalized Approach

The company Mymee recently published a study on their personalized digital care program for patients living with autoimmune diseases as well as long Covid. Researchers found that over 85% of patients with moderate to severe symptoms saw improvements with their anxiety, depression, fatigue, pain interference, sleep disturbance, and pain intensity while increasing cognitive and physical function.

Read More »

COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

Researchers evaluated the characteristics, severity, course of infection, and disease outcomes in COVID-19 patients with and without Systemic Autoimmune Rheumatic Diseases (SARDs). Patients with rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren’s syndrome, Psoriasis, Type 1 Diabetes, Inflammatory Bowel Disease, and Glomerulonephritis, amongst others, were included in the study. 

Read More »